Cassava Sciences, Inc. (SAVA)
After hours:
| Previous Close | 54.62 |
| Open | 54.59 |
| Bid | 52.77 x 1300 |
| Ask | 53.50 x 2900 |
| Day's Range | 49.62 - 55.89 |
| 52 Week Range | 6.70 - 146.16 |
| Volume | |
| Avg. Volume | 7,154,960 |
| Market Cap | 2.14B |
| Beta (5Y Monthly) | 0.51 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.56 |
| Earnings Date | Nov. 10, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Dec. 13, 2012 |
| 1y Target Est | 159.25 |
- Zacks
Is the Options Market Predicting a Spike in Cassava Sciences (SAVA) Stock?
Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.
- Zacks
Biogen's (BIIB) Aducanumab Gets CHMP's Negative Trend Vote
Biogen's (BIIB) regulatory application seeking approval for its Alzheimer's drug, Aduhelm, in Europe hits setback as it receives negative trend vote from the CHMP.
- GlobeNewswire
Cassava Sciences Initiates a Second Phase 3 Study of Simufilam for the Treatment of Patients with Alzheimer’s Disease
Second Phase 3 Study is Designed to Evaluate Safety and Efficacy of Simufilam Over 78 Weeks in 1,000 Patients with Alzheimer’s DiseaseAUSTIN, Texas, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, announced today it has initiated a second Phase 3 study of simufilam, the Company’s investigational drug for patients with Alzheimer’s disease. This second Phase 3 study is designed to evaluate the safety and efficacy of simufilam over 78 weeks in appro
